U.S. FDA grants fast track designation to HC-7366 for the treatment of R/R AML
On October 23, 2024, the U.S. Food and Drug Administration (FDA) granted fast track designation to HC-7366, a GCN2-targeting agent, for the treatment of patients with R/R AML.